Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AVXL

AVXL - Anavex Life Sciences Corp Stock Price, Fair Value and News

$4.86-0.19 (-3.76%)
Market Closed

20/100

AVXL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

AVXL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.21

Target 3M

$4.73

Target 6M

$4.47

AVXL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVXL Price Action

Last 7 days

-8.3%

Last 30 days

33.2%

Last 90 days

-39.5%

Trailing 12 Months

-51.0%

AVXL RSI Chart

AVXL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVXL Valuation

Market Cap

434.2M

Price/Earnings (Trailing)

-9.36

Price/Sales (Trailing)

47.21

EV/EBITDA

-7.95

Price/Free Cashflow

-11.12

AVXL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.21

Target 3M

$4.73

Target 6M

$4.47

AVXL Fundamentals

AVXL Revenue

Revenue (TTM)

9.2M

AVXL Earnings

Earnings (TTM)

-46.4M

Earnings Growth (Yr)

15.43%

Earnings Growth (Qtr)

25.79%

AVXL Profitability

EBT Margin

-504.21%

Return on Equity

-48.89%

Return on Assets

-44.67%

Free Cashflow Yield

-8.99%

AVXL Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

-0.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.6M6.9M9.2M0
20242.5M2.2M2.4M0
202311.9M7.3M2.7M0
20220021.0M16.4M
202131.6M55.3M79.1M50.0M
20203.0M3.7M7.5M7.8M
20192.8M1.7M2.5M3.0M
201803.7M1.6M2.0M
20171.1M1.5M2.0M0
2016781.4K758.1K571.1K0
2015000776.9K
2013131.3K129.2K176.3K182.6K
2012165.4K150.6K142.9K139.2K
201191.1K124.7K158.2K180.0K
20100024.1K57.6K
Get all data in R, Python etc through our Historical Stock Data APIs

About Anavex Life Sciences Corp

AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
 CEO
 WEBSITEanavex.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES38

Anavex Life Sciences Corp Frequently Asked Questions

AVXL is the stock ticker symbol of Anavex Life Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Anavex Life Sciences Corp is 434.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AVXL's fair value in chart for subscribers.

The fair value guage provides a quick view whether AVXL is over valued or under valued. Whether Anavex Life Sciences Corp is cheap or expensive depends on the assumptions which impact Anavex Life Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVXL.

As of Wed Jan 28 2026, AVXL's PE ratio (Price to Earnings) is -9.36 and Price to Sales (PS) ratio is 47.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVXL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Anavex Life Sciences Corp has provided 0.031 (multiply by 100 for percentage) rate of return.